Mathilde Cancel

1.0k total citations
28 papers, 421 citations indexed

About

Mathilde Cancel is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Mathilde Cancel has authored 28 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 6 papers in Surgery. Recurrent topics in Mathilde Cancel's work include Renal cell carcinoma treatment (6 papers), Prostate Cancer Treatment and Research (6 papers) and Ovarian cancer diagnosis and treatment (4 papers). Mathilde Cancel is often cited by papers focused on Renal cell carcinoma treatment (6 papers), Prostate Cancer Treatment and Research (6 papers) and Ovarian cancer diagnosis and treatment (4 papers). Mathilde Cancel collaborates with scholars based in France, United States and Canada. Mathilde Cancel's co-authors include Laurence Albigès, Jae‐Lyun Lee, Sabina Signoretti, Daniel Y.C. Heng, Toni K. Choueiri, Florina Moldovan, Lone H. Ottesen, Zsolt Szíjgyártó, Anders Mellemgaard and Guy Grimard and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and International Journal of Molecular Sciences.

In The Last Decade

Mathilde Cancel

25 papers receiving 415 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mathilde Cancel France	8	236	192	84	77	72	28	421
Nobuyuki Sekita Japan	12	207 0.9×	206 1.1×	86 1.0×	31 0.4×	57 0.8×	33	478
Krinio Giannikou United States	12	189 0.8×	123 0.6×	101 1.2×	34 0.4×	35 0.5×	23	459
Karen Krchma United States	9	224 0.9×	62 0.3×	52 0.6×	79 1.0×	52 0.7×	13	421
Abraham Behrmann United States	8	240 1.0×	101 0.5×	43 0.5×	164 2.1×	46 0.6×	9	635
Jacqueline F. Schmitt Australia	10	341 1.4×	137 0.7×	93 1.1×	115 1.5×	55 0.8×	16	562
Zhen‐Kui Sun China	15	150 0.6×	75 0.4×	111 1.3×	27 0.4×	105 1.5×	38	525
Sylvie Rothhut France	12	422 1.8×	144 0.8×	150 1.8×	32 0.4×	159 2.2×	14	548
Kiyoaki Inoue Japan	5	285 1.2×	68 0.4×	61 0.7×	61 0.8×	99 1.4×	9	524
Robert B. Good United Kingdom	8	237 1.0×	468 2.4×	42 0.5×	22 0.3×	73 1.0×	9	713
Sumegha Mitra United States	12	250 1.1×	66 0.3×	125 1.5×	30 0.4×	94 1.3×	16	486

Countries citing papers authored by Mathilde Cancel

Since Specialization

Citations

This map shows the geographic impact of Mathilde Cancel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathilde Cancel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathilde Cancel more than expected).

Fields of papers citing papers by Mathilde Cancel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathilde Cancel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathilde Cancel. The network helps show where Mathilde Cancel may publish in the future.

Co-authorship network of co-authors of Mathilde Cancel

This figure shows the co-authorship network connecting the top 25 collaborators of Mathilde Cancel. A scholar is included among the top collaborators of Mathilde Cancel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathilde Cancel. Mathilde Cancel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Auclin, Édouard, Clément Dumont, H. Gauthier, et al.. (2026). Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer. 24(2). 102506–102506.

Dumont, Clément, Guilhem Roubaud, Damien Pouessel, et al.. (2025). Feasibility and efficacy of cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer in older patients: A retrospective French GETUG study.. Journal of Clinical Oncology. 43(5_suppl). 735–735.

Fizazi, Karim, Gwénaël Le Teuff, Aude Fléchon, et al.. (2024). Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. Journal of Clinical Oncology. 42(28). 3270–3276. 4 indexed citations

Ouldamer, Lobna, et al.. (2024). Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature. The Oncologist. 29(7). e910–e917. 1 indexed citations

Cancel, Mathilde, et al.. (2024). FASTOCH: Feasibility of Electronic Patient-Reported Outcomes in Older Patients With Cancer—A Multicenter Prospective Study. Journal of Clinical Oncology. 42(22). 2713–2722. 7 indexed citations

Dardaine, Véronique, et al.. (2024). Geriatric factors associated with overall survival in older patients with metastatic colorectal cancer. Clinics and Research in Hepatology and Gastroenterology. 48(2). 102280–102280. 1 indexed citations

Cancel, Mathilde, et al.. (2024). Oncologists’ perspective on advance directives, a French national prospective cross-sectional survey – the ADORE study. BMC Medical Ethics. 25(1). 44–44. 1 indexed citations

Duffaud, Florence, Jean‐Yves Blay, Axel Le Cesne, et al.. (2023). Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study. British Journal of Cancer. 129(12). 1940–1948. 17 indexed citations

Cancel, Mathilde, David Crottès, Dorine Bellanger, et al.. (2023). Variable effects of periprostatic adipose tissue on prostate cancer cells: Role of adipose tissue lipid composition and cancer cells related factors. The Prostate. 84(4). 358–367. 1 indexed citations

10.

Thibault, Constance, Mostefa Bennamoun, Aude Fléchon, et al.. (2023). 2364MO Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial. Annals of Oncology. 34. S1202–S1202. 5 indexed citations

11.

Laurent, Émeline, et al.. (2022). Impact of Novel Hormonal Agents (Abiraterone, Enzalutamide) on the Development of Visceral and/or Brain Metastases in Patients With Bone-metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer. 20(5). 495.e1–495.e9.

12.

Albigès, Laurence, Daniel Y.C. Heng, Jae‐Lyun Lee, et al.. (2022). Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data. European Journal of Cancer. 170. 158–168. 7 indexed citations

13.

Cancel, Mathilde, et al.. (2022). Interplay between Prostate Cancer and Adipose Microenvironment: A Complex and Flexible Scenario. International Journal of Molecular Sciences. 23(18). 10762–10762. 18 indexed citations

14.

Cancel, Mathilde, Maxime Guéguinou, Marie Potier‐Cartereau, et al.. (2021). Zeb1 and SK3 Channel Are Up-Regulated in Castration-Resistant Prostate Cancer and Promote Neuroendocrine Differentiation. Cancers. 13(12). 2947–2947. 11 indexed citations

15.

Auclin, Édouard, Brigitte Laguerre, Mathilde Cancel, et al.. (2021). Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer. Cancer Medicine. 10(18). 6304–6309. 7 indexed citations

16.

Cancel, Mathilde, G. Body, Sofiane Bendifallah, et al.. (2021). Lymphovascular invasion as a criterion for adjuvant chemotherapy for FIGO stage I-IIa clear cell carcinoma, mucinous, low grade serous and low grade endometrioid ovarian cancer. Journal of Gynecology Obstetrics and Human Reproduction. 50(10). 102193–102193. 2 indexed citations

17.

Cancel, Mathilde, Aurélie Chantôme, Roseline Guibon, et al.. (2020). The Calcium-Sensing Receptor is A Marker and Potential Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancers. 12(4). 860–860. 23 indexed citations

18.

Duffaud, Florence, Jean‐Yves Blay, Olivier Mir, et al.. (2020). LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER. Annals of Oncology. 31. S1199–S1199. 13 indexed citations

19.

Trédan, Olivier, Cyril Abdeddaim, Sylvie Chabaud, et al.. (2020). 829P Regorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: A GINECO randomized phase II trial. Annals of Oncology. 31. S624–S625. 1 indexed citations

20.

Cancel, Mathilde, et al.. (2008). Effects of in vivo static compressive loading on aggrecan and type II and X collagens in the rat growth plate extracellular matrix. Bone. 44(2). 306–315. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact